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 Abstract 
Hungary is at the forefront as regards occurrence of diseases, 
which would be preventable by continuing consciously lifestyle. 
Thereby, in the long run expenditures those spend for medical 
care would be saved in government level. At the same time, not 
all forms of disease prevention able to cause beneficially effect 
proved statistically. My starting hypothesis is about that in 
Hungarian regions where the number of diseases is lower due 
to the health-conscious lifestyle, so the OEP financing due for 
the lower case numbers per capita, relatively more money is 
spent on non-prescription (OTC) drug consumption, namely 
total household expenditures spending on pharmaceuticals are 
higher than level which could be assume based on the number 
and frequency of morbidity. I have concluded that the role of 
self-medication inside of drug consumption is not influence the 
regional medical care expenditure per capita. 
1 Introduction  
According to the WHO estimates, within the group of non-communicable diseases the 
majority of death cases are still caused by cardiovascular diseases, “its proportion was more than 
40% of the all mortality in the developed countries at the beginning of the new millennium” [1]. 
Among them Hungary belongs to countries characterized by high risk of diseases. As a result, if 
the prevention in population level would be a prominent role, thus it can couple with financial 
impact to the budget of health care system. However Ádány [2] highlights the paradox of 
prevention: although in relation to the population would be very effective, for the individuals 
involved in it is rarely perceived such direct, personal advantage. Although “in explanation of 
macro- and micro-level allocation decisions in health care, the impact to expenditures can only be 
included in second place” [3], many people believe that scarcity of finite resources limits the 
opportunities for maintaining health.  
Treatment of disease prevention as priority for a population where lifestyle habits different 
significantly from that required by the health protection, reallocate of significant part of scarce 
resources (spendable income, free time) is necessary. In turn this can only be next to resignation 
from satisfy of certain individual needs those member of population or postpone, either try to 
achieve with consumption of additional products typically that can include extra spending avoiding 
the perceived difficulties associated with lifestyle change, depending of the possibilities and the 
adherence to former habits. Within the pharmaceuticals market, this phenomenon manifests mostly 
in turnover of drugs obtained without a prescription (can be sold outside pharmacies, from initials 
of “Over the counter” OTC).  
According to Kaló [4] this latter part of pharmaceutical turnover calculated in free market 
price entails the biggest uncertainties among estimates associated with the pharmaceutical 
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spending of households. In the early 2010s, IMS Health “predicted world drug market slowdown in 
the growth, only 3-6% market growth” [5]. Within the Hungarian pharmaceutical market in 2013, 
"the total drug sales with the outsides pharmacies 5-6 billion Ft sales calculated on consumer 
prices, and the hospital medicine turnover 144-146 billion Ft calculated on producer prices 
approached the 730 billion Ft” [6]. As it can see in Figure 1 the rate of turnover of OTC medicines 
is the second largest following Poland in the EU in third quarter of 2014. 
 
 
Figure 1. Rate of OTC drug turnover within the total medicine turnover.  
Source: MAGYOSZ, IMS Health, 2015. 
The increase in sales of OTC medicines promoted the fact that "in recent years, pharmacies 
have become interested in optimizing their economic situation, the gross margin loss caused by 
the prescription drugs is tried to compensate with recommendation of drugs those can enable 
without prescription and has higher margin" [7]. 
2 Material and method 
My starting hypothesis is that self-medication may contribute to decrease of patient care 
expenditures through health consciousness, namely, in those regions where the health situation of 
population is better the OTC pharma consumption is relatively higher too. “The epidemiological 
research tested on health state of population usually based on relative numbers, however it 
measure the »sickness« and not the »health« state” [8], such as the prevalence of certain diseases 
or the number of deaths. On my study the comparison of health status of regions realized through 
National Health Insurance Found (OEP) financing after the incidence of patient care of health care 
providers for each region. The analysis is based on regional data collection related to the Central 
Statistical Office for domestic consumption and data from National Health Insurance Found (OEP) 
related to health producer financing and reimbursed medicine turnover. 
Since the National Health Insurance database covers only prescription pharmaceuticals 
turnover, furthermore the Central Statistical Office’s data on household consumption makes no 
distinguish between prescription and non-prescription medicines expenditure, the OTC drug 
market values can calculated by difference of pharmaceutical expenditure per capita recognized in 
regional level and prescription tuition fee turnover of pharmaceutical products per capita (on 
consumer prices reduced grant amount). It expresses the following equation, where OTC is the 
consumption of medicine without prescription. 
 
(1) 
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Patient care costs calculation based on regional summaries of OEP amounts of aid assigned 
to medical services registered in the country level. The cost data has calculated after adjusting for 
health care inflation, on data base of 2006, without a reimbursement of pharmaceutical products, 
because the purpose of this research limits only to the impact of OTC pharma product 
consumption, which are not supported by the Social Insurance. The investigation of relationship 
between drug consumption and cost of patient care realize used by SPSS, regression and analysis 
of variance (ANOVA) method. 
3 Results 
The household expenditures inverted to OTC drugs per capita increase by 10.9% nationwide 
compared to 2006, in the following 8 years in average, while the trend of sales growth fell only in 
2010 in all regions, partly due to the economic crisis, in part due to the fact that a significant 
increase in traffic in all regions in 2009 resulted in a high base data. The Hospital Association’s 
analysis published in 2014 explains the national turnover growth in OTC segment occurring despite 
becoming prescribed Algopyrin, the change of support and prescribing system. The cost of patient 
care calculated on base prices of 2006 shows declining trend in accordance with changes in the 
rate of OTC pharmaceutical expenditure, there was increase only in 2010 and in 2013 in national 
level.  
 
 
Figure 2. Annual average of medicine expenditures per capita and cost of patient case in the 
Hungarian regions (2006-2013). Source: own edition. 
Based on analysis of regional data it can show that the cost of patient care similar to the 
consumption of OTC drugs per capita is the highest in the Central Hungary region. Since the 
impact of population in different regions filtered in per capita indicators, outstanding value typical of 
this region can explain not with population approximating third of the country’s total population, 
neither with, but mainly with economic and development indices and higher disposable income per 
capita relative to other regions, which can enable on the one hand easier availability of OTC 
medicinal products, advanced infrastructure network for health services, on the other hand a 
relatively higher level of demand for pharmaceutical products in OTC segment. The outstanding 
value of cost of patient care per capita also implies that funding case number is higher than value 
justified by population, so the higher frequency of occurrence of diseases can be traced back to the 
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differences in lifestyle due to the improved economic-infrastructural environment. This was not able 
to offset by rate of 58% of OTC medicine expenditures within the total medicine expenditures per 
capita in the examined eight years after 2006. The total spending on drugs and within that, the size 
and proportion (47%) of OTC drug expenditure in West Transdanubia region showed the lowest 
value, since the cost of patient care per capita in South Transdanubia region is the biggest.  
The consumption of prescription medicines per capita exceeded at annual average the 
consumption of OTC medicines only in West and South Transdanubia region, in South Great Plain 
their size was only slightly different from each other. If we examine only the impact of OTC 
medicine consumption, so based on results of variance analysis – which summarized in Table 1 – 
the null hypothesis, related to the lack of connection between the level of regional self-medication 
and costs of patient, care can accepted, because the F significance (5.3%) value expressed by 
probability of incorrect rejection of the null hypothesis is higher than significance level of 5% that 
assumed in the model. Therefore, there is no significant difference between costs of patient care in 
terms of regional differences of OTC pharmaceutical expenditures. 
Table 1. Results of variance and correlation analysis. 
 R 
R 
Square 
Adjusted 
R 
Square 
Std. Error 
of the 
Estimate 
Change statistics 
R Square 
change 
F change df1 df2 Sig. F 
Model 
1 .748* .560 .472 8974.549 .560 6.359 1 5 .053 
2 .811** .658 .488 8838.698 .099 1.155 1 4 .343 
*Predictors: (Constant), OTC drug consumption 
**Predictors: (Constant), OTC drug consumption, Prescription drug consumption 
Source: own edition by using SPSS. 
 
At the same time, however this difference is small enough in order to the close of 
relationships between the former two factors has not be confirmed that, whereas the correlation 
coefficient shows a relatively high value (0.75). This slightly strong relationship is also supported by 
that OTC drug turnover explains a variance of cost of patient case in 56%.  
Table 2. Results of regression analysis 
 Coefficients 
Standard 
error 
t value p-value Bottom 95% Top 95% 
Intercept -1611.17 25459.8401 -0.063 0.952 -67057.7 63835.44 
OTC drug 
consumption 5.76796 2.28739 2.52 0.053 -0.1119 11.6479 
Source: own edition 
 
According to data arise from regression statistics if OTC medicine consumption misses, it 
can save more expenditure in the field of health care: a change of Ft 1 in the household spending 
for medicines without prescription causes in average more than growth of Ft 5 in health care 
expenditures at National Insurance, however the relatively high p-value does not confirm the 
accuracy of that. 
4 Conclusions 
All in all, from analysis of composition of pharmaceutical market turnover and from results of 
variance analysis it can conclude that the OTC drug consumption itself, significantly has not 
affected the development of health expenditures, namely consumption of OTC medicine products 
should not replace alleged difficulties associated with lifestyle change that is needed: with higher 
self-medication could reduce significantly nor the probability of occurrence of diseases, neither the 
number of cases no funding. So the government would only able to save more health expenditures 
through prevention, if it would take people interested in lifestyle changes (for example in nutrition, 
sport) instead of changes of drug consumption habits.  
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